Related Experiment Video
Updated: Aug 6, 2026

Supercritical Nitrogen Processing for the Purification of Reactive Porous Materials
Published on: May 15, 2015
Preparation of budesonide/gamma-cyclodextrin complexes in supercritical fluids with a novel SEDS method
Tarja Toropainen1, Sitaram Velaga, Teemu Heikkilä
1Department of Pharmaceutical Chemistry, University of Kuopio, P.O. Box 1627, F1-70211 Kuopio, Finland. tarja.toropainen@uku.fi
Abstract:
The aim was to investigate if solid drug/cyclodextrin complexes could be produced in a single-step process with a solution enhanced dispersion by supercritical fluids (SEDS) method. Budesonide and gamma-cyclodextrin (CD) solutions (50% or 99.5% ethanol) were pumped from the same (conventional method) or separate (modified method) containers together with supercritical carbon dioxide through a coaxial nozzle into a particle formation chamber. The pressure was maintained at 100, 150 or 200 bar with a temperature of 40, 60 or 80 degrees C. SEDS-processed powders were characterised with HPLC, DSC and XRPD for budesonide content, complexation and crystallinity. The budesonide dissolution rate was determined in 1% gamma-CD aqueous solution. Solid, white budesonide/gamma-CD complex particles were formed using the conventional and modified SEDS processes. The complexation efficiency was dependent on the processing conditions. For example, with the conventional method (100 bar, 60 degrees C) the yield of the powder was 65+/-12% with 0.14+/-0.02 mg budesonide/mg powder, corresponding to 1:2 drug:CD molar ratio. The dissolution rate of this complexed budesonide (93+/-2% after 15 min) was markedly higher compared to unprocessed micronised budesonide (41+/-10%) and SEDS-processed budesonide without CD (61+/-3%). As a conclusion, SEDS is a novel method to produce solid drug/CD complexes in a single-step process.
Related Concept Videos
Supercritical Fluid Chromatography
SFC utilizes a supercritical fluid mobile phase,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Bioavailability Enhancement: Drug Solubility Enhancement
